Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer

Executive Summary

Will submit two NDAs over the next 12 months, including the oral antibiotic Unasyn (sultamicillin) and an azolide antibiotic azithromycin, firm reported at April 27 annual meeting. An injectable form of Unasyn (sulbactam/ampicillin) was approved for U.S. marketing in December 1987. Pfizer currently has eight NDAs pending at FDA, the company said. Among drugs pending agency approval are the antifungal Diflucan (fluconazole), filed March 1, Xomen-E5, Xoma's monoclonal antibody-based treatment for gram negative sepsis developed in conjunction with Pfizer, Procardia XL, Minipress XL, the vasodilator Cardura (see related story), Norvasc, the anti-depressant sertraline, and the selective antihistamine cetirizine.

You may also be interested in...



Congress Set To Approve CR, Freezing FDA Spending Level For Next Three Months

The US agency’s 2021 device funding request for $21m above its 2020 budget will be frozen under a continuing resolution, making planning difficult.

Head Of New Digital Health Center Looking For A Few Good FDA Staff

Bakul Patel, director of the US agency’s new Digital Health Center of Excellence, tells Medtech Insight he’s looking to hire staff that want to shape the digital health regulatory landscape.

Warning Letter Roundup & Recap – 29 September 2020

No device-related warning letters were released by the US FDA the week of 29 September.

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel